Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PBLA |
---|---|---|
09:32 ET | 23127 | 0.43 |
09:43 ET | 135 | 0.42 |
10:03 ET | 5188 | 0.42 |
10:08 ET | 100 | 0.42 |
10:10 ET | 100 | 0.41 |
10:14 ET | 600 | 0.4 |
10:44 ET | 800 | 0.4198 |
11:22 ET | 595 | 0.4 |
12:14 ET | 200 | 0.412 |
01:50 ET | 1000 | 0.42 |
02:24 ET | 6000 | 0.42 |
02:31 ET | 5000 | 0.42 |
03:09 ET | 2000 | 0.4 |
03:27 ET | 3000 | 0.41 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Panbela Therapeutics Inc | 2.1M | 0.0x | --- |
VG Life Sciences Inc | 2.1M | 0.0x | --- |
CNS Pharmaceuticals Inc | 2.2M | 0.0x | --- |
CTT Pharmaceutical Holdings Inc | 2.1M | -0.5x | --- |
Mosaic Immunoengineering Inc | 2.3M | -2.2x | --- |
Dermata Therapeutics Inc | 2.3M | -0.1x | --- |
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI). Flynpovi is a combination of CPP-1X (eflornithine) and sulindac. It has a dual mechanism of action whereby it suppresses the synthesis of new polyamines and increases the export and catabolism of polyamines from the diet and microbiome. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes metastatic castration-resistant prostate cancer, and STK-11 mutant NSCLC.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 4.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.84 |
EPS | $-184.67 |
Book Value | $-9.81 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.